Amarin Receives National Reimbursement for VAZKEPA (icosapent ethyl) in Portugal
The Portuguese Ministry of Health has recently granted national reimbursement approval for VAZKEPA (icosapent ethyl), a medication designed to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD). This decision marks the eighth European country to provide national reimbursement for VAZKEPA.
VAZKEPA, developed by Amarin, has demonstrated its efficacy in reducing the incidence of CV events in multiple clinical trials. The medication contains icosapent ethyl, a form of prescription omega-3 fatty acid, which has shown positive outcomes in improving cardiovascular health.
The approval for national reimbursement of VAZKEPA by the Portuguese Ministry of Health indicates the recognition of the medication’s value in managing cardiovascular risk in patients with established CVD. By making VAZKEPA more accessible and affordable, this decision is expected to improve patient access to an effective treatment for reducing the risk of CV events.
In addition to Portugal, VAZKEPA has already received national reimbursement in seven other European countries, including Germany, the United Kingdom, and Ireland. These approvals reflect the growing recognition of the medication’s benefits in reducing the burden of cardiovascular diseases across Europe.
The inclusion of VAZKEPA in national reimbursement programs not only expands patient access but also highlights its significance in cardiovascular disease management. Patients with established CVD can now avail themselves of this innovative treatment option, which has the potential to significantly reduce their risk of future CV events.
In conclusion, the Portuguese Ministry of Health’s recent approval for national reimbursement of VAZKEPA in Portugal is a significant development in the management of cardiovascular diseases. The inclusion of VAZKEPA in the country’s reimbursement program provides patients with established CVD greater access to a medication that has proven efficacy in reducing the risk of CV events. This decision contributes to improving patient outcomes and represents another important milestone in the recognition of VAZKEPA’s value in addressing the burden of cardiovascular diseases.
Comments